-
With the continuous efforts of pharmaceutical companies, domestic Class 1 antidepressant innovative drugs have been approved for marketing
Time of Update: 2023-01-07
According to incomplete statistics, more than ten Class 1 innovative drugs in the field of depression research and development in China have been approved for clinical trial and above, involving many enterprises such as Haosen Pharmaceutical, Huahai Pharmaceutical, Salubris Pharmaceutical, Luye Pharmaceutical, CSPC Pharmaceutical Group, Enhua Pharmaceutical and so on.
-
Amoxicillin/clavulanate potassium, did you use it correctly
Time of Update: 2023-01-06
Download the Decision Assistant App and check it anytime, anywhere~References:[1] Chinese Medical Association, Chinese Medical Association Clinical Pharmacy Branch, Chinese Medical Association Journal Society, Chinese Medical Association General Practice Branch, Chinese Medical Association "Chinese Journal of General Practitioners" Editorial Board, Expert Group for Rational Drug Use Guidelines for Primary Medical and Health Institutions.
-
Amoxicillin/clavulanate potassium, did you use it correctly
Time of Update: 2023-01-06
Download the Decision Assistant App and check it anytime, anywhere~References:[1] Chinese Medical Association, Chinese Medical Association Clinical Pharmacy Branch, Chinese Medical Association Journal Society, Chinese Medical Association General Practice Branch, Chinese Medical Association "Chinese Journal of General Practitioners" Editorial Board, Expert Group for Rational Drug Use Guidelines for Primary Medical and Health Institutions.
-
Industry: Domestic innovative drugs are ushering in a good era of FIC and BIC
Time of Update: 2023-01-05
In addition to Hengrui and Fosun, many pharmaceutical companies entering the field of innovative drugs have continued to increase investment in R&D, and the number of new drugs approved in China has reached a record high.
-
Sino Shenzhou helps the cell blue ocean market and boosts new breakthroughs in the cell biological industry
Time of Update: 2022-10-01
On the morning of September 20th, the "2022 (13th) Cell Therapy Conference" co-sponsored by Biovalley, Shanghai Oriental Hospital, Tongji Hospital Affiliated to Tongji University, and Chinese Health S
-
Out of stock to book, gross profit margin 50% This kind of product is very popular recently
Time of Update: 2022-04-24
On the same day, the People's Pharmacy in Changsha City, Hunan Province also put on the shelves the new crown antigen self-testing agent (produced by Tianjin Boaosaisi), the specification is 5 people / box, the price is 72.
-
breakthrough
Time of Update: 2022-02-19
Another domestic CAR-T product obtained orphan drug qualification Recently, Heyuan Bio and the Chinese Academy of Medical Sciences Hematology Hospital jointly announced that its self-developed targeting CD19 CAR-T drug CNCT19 cell injection has obtained orphan drug qualification granted by the US FDA , for the treatment of acute lymphoblastic leukemia .
-
The main problems found in Xinjiang's 8 batches of unqualified food are microbial contamination, use of food additives, etc
Time of Update: 2022-02-18
121，，“”，、、、4320，8，、 。 5 Among the unqualified samples, 5 batches of samples were found to have microbial contamination problems. They are: The business address is Shop 1-4, Commercial Building
-
"Innovative Drug One Brother" is amazing
Time of Update: 2022-01-10
According to data from Meinenet, in the past week, Hengrui Medicine has 7 new drugs (6 of which are Class 1 new drugs) for clinical application .
-
The Waigaoqiao base of Hequan Pharmaceutical successfully passed the pre-market inspection of the U.S. FDA for its first preparation project
Time of Update: 2022-01-07
This is the first time that the Waigaoqiao base has completed the FDA pre-market approval inspection for the preparation project, which will help Hequan Pharmaceutical to better provide preparation commercial production services for global customers .
-
Luye Pharma's innovative drug Liss' Mingdo Day transdermal patch obtained EU multi-country marketing authorization qualification
Time of Update: 2021-06-01
Luye Pharmaceutical Group announced that its self-developed innovative preparation, Liss’ Mindo Day transdermal patch, has successfully passed the EU decentralized review process.
-
How to solve the "Chinese characteristics" blood sugar problem
Time of Update: 2021-04-14
The "Guide" emphasizes [4] that, based on the combination of lifestyle and oral hypoglycemic drugs, patients with T2DM should initiate insulin therapy as soon as possible if the blood sugar has not reached the control goal.
It can be seen that Degu aspart insulin reduces the risk of hypoglycemia while controlling blood sugar [15 ].
-
Hesco cyclophenol injections are approved for listing by the NMPA
Time of Update: 2020-12-24
Source: MED2.0 China Drug Review Database Cyclophenol is GABAA-subjected atrial asticity sedative.
approved this time, making it the third new Class 1 drug to go on sale this year.
-
Cell Metabol: Breakthrough! Scientists may be expected to target metabolic changes in acting cells to remove drug-resistant cancer cells
Time of Update: 2020-09-11
researcher Gastel points out that these changes may not be visible when the cancer begins to relapse late, a short-lived stress response in which cancer cells become very vulnerable if they target the metabolism of cancer cells, and when researchers use only one day to target the metabolism of cancer cells or nucleotides, drug-resistant cancer cells are eliminated and the patient's disease symptoms improve.
-
China's drug patent link to come, generic drug enterprises how to deal
Time of Update: 2020-08-12
Guide: This paper analyzes the establishment and implementation progress of China's drug patent compensation system and drug link system by comparing the relevant drug patent systems in various countr
